Oridion Expands its Presence in the Pre-hospital Market with an OEM Partnership with a leading Defibrillator Manufacturer

Oridion today announced that it signed an OEM agreement with a leading global manufacturer of resuscitation devices. With this agreement, Oridion Microstream® capnography solutions will be incorporated into a defibrillator monitoring system at a future date.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Jerusalem/Needham, MA (PRWEB) May 25, 2009

Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN) today announced that it signed an OEM agreement with a leading global manufacturer of resuscitation devices. With this agreement, Oridion Microstream® capnography solutions will be incorporated into a defibrillator monitoring system at a future date.

The patented Microstream® end tidal carbon dioxide (etCO2) measurement technologies and proprietary breath sampling (FilterLine®) products improve patient safety by providing the earliest assessment of a patient's ventilatory status in both intubated and non intubated patients.

Researchers have shown that capnography is an important tool during emergency applications. It has, for example, proven far superior in recognizing misplaced endotracheal tubes when compared to traditional clinical subjective evaluations(1). Other studies show that etCO2 levels should be monitored during CPR (Cardiopulmonary resuscitation) and should be regarded as having important prognostic value in predicting the outcome of resuscitative efforts(2).

Gerry Feldman, President of Oridion Systems Ltd., said: "We are very proud to have entered into this agreement. It demonstrates further recognition of the value Microstream respiratory solutions bring to the emergency care market. This alliance combines our newest partner's formidable strength in defibrillator/monitor products with Oridion global leadership in capnography technology in order to improve patient safety and patient outcomes."

(1) Silvestri S, Ralls GA, Krauss B, et al. The effectiveness of out of hospital use of continuous end tidal carbon dioxide monitoring on the rate of unrecognized misplaced intubation within a regional emergency medical services system. Ann Emerg Med 45(5):497 503, 2005.
(2) Miran K, Miljenko K, et al. Partial pressure of end tidal carbon dioxide successful predicts cardiopulmonary resuscitation in the field: a prospective observational study, Critical Care 2008, 12:R115 (doi:10.1186/cc7009)

For further Oridion information please contact
Alan Adler, Chairman and Chief Executive Officer
Walter Tabachnik, Chief Financial Officer
Elena Gerberg, Investor Relations

website: http://www.oridion.com
e-mail: investor (at) oridion (dot) com
phone: +972 2 589 9159
address: Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel

About Oridion
Oridion Systems Ltd. (http://www.oridion.com ) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States, Europe, and Israel.

Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream® technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology.

Furthermore, this press release does not constitute an offer to sell or a solicitation of an offer to buy any securities. The Company's shares issued have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant Securities Laws of any state of the United States. The Company's shares may not be offered, sold or delivered, directly or indirectly, to, or for, the account of any US person (as defined in regulation S under the Securities Act) in or into the United States, or by use of the US mail, or by any means or instrumentality of United States interstate commerce, absent registration, or an exemption from registration under the Securities Act.

###


Contact